The Department of Radiation Oncology. In loving Memory of Penny Slattery ( ) Medical Physics Journal Manager ( )
|
|
- Amber French
- 6 years ago
- Views:
Transcription
1 The Department of Radiation Oncology In loving Memory of Penny Slattery ( ) Medical Physics Journal Manager ( )
2 The Department of Radiation Oncology Medical Physics Workshop: Editorial Vision and Guidance on Writing and Reviewing Papers Jeffrey F. Williamson, Ph.D. Medical Physics, Editor-in-Chief Shiva K. Das, Ph.D. Medical Physics, Therapy Physics Editor Mitchell M. Goodsitt, Ph.D. Medical Physics, Imaging Physics Editor
3 Tribute to Penny Med Phys, April 2015
4 Outline Jeff Williamson: Editorial vision and status of new initiatives Shiva Das: Guidelines and templates for Referees and Associate Editors Mitch Goodsitt: Writing good scientific papers and responding to critiques
5 The Department of Radiation Oncology Editorial Vision for Medical Physics Update and current status of new initiatives Jeffrey F. Williamson, Ph.D. Virginia Commonwealth University Medical Physics, Editor-in-Chief
6 Outline Core values and mission Recent initiatives and changes to Med Phys operations Outcomes Ongoing initiatives
7 Medical Physics: Core Mission Enhance Medical Physics status as the preeminent forum for exchange of cutting edge medical physics science To identify and publish the best contributions in cutting edge basic science developments with potential for improving patient care clinical translation and validation of previously developed basic science innovations High impact clinical physics innovations that solve a significant clinical problem of broad interest Features of a publishable articles Novelty Generalizable scientific data or conclusion Relevant to significant subset of our readership
8 Vision and Mission Statement Bill Hendee (2005): to continue the Journal s tradition of publishing the very best science that propels our discipline forward and improves our contribution to patient care. The discipline is broad: application of physics concepts and methods to diagnosis and treatment of disease Medical imaging: pyscho-physics, system design, image reconstruction/restoration» X-rays, US, MR, RF, etc. for anatomic, biomechanical, electrical, molecular, and physiological properties Therapy: platform design, optimization, planning, dosimetry, outcome/biology models, imaging for response and guidance» RT, IG surgery, RF/US oblation and thermal therapy Basic research:» Segmentation, registration, feature extraction, voxel labeling» Image quality assessment and dosimetry» Physiology, biology, statistics
9 Editorial Model With growth of journal, Editor s responsibility has evolved into a full-time position Starting January, 2014, a new model Jeff Williamson, Editor-in-Chief (50%) Mitch Goodsitt, Imaging Physics Editor (25%) Shiva Das, Therapy Physics Editor (25%) Transitioning to in-house Board of Associate Editors Currently, 140 members including Editorial Board 74% of new submissions were managed by inhouse AEs
10 Review Process: 2-3 cycles 1. Ms. Received: Editor-in-Chief (EIC) Selects editor (ED) 2. ED preliminary review a. Rejects paper (15%) OR b. Recruits associate Editor (AE) 3. AE manages review a. Solicits reviews from at least 2 referees b. Makes recommendation to ED 4. Editorial Decision a. ED reviews Ref and AE reviews b. Makes decision and communicates to Author c. EIC signs off on ED decision
11 Ms. Processing and Author Interface Penny: the face of the journal for 20 years Author submissions, questions, reminders Very difficult late 2014, early 2015 Penny quite ill or undergoing treatments with sudden and rapid decline in late February Many innovations and QA systems on hold Hundreds of accumulated s and Ms. New model Interim Editorial Assistant: Ania Bukowski (AIPP)» Handles all Ms processing, author queries, review team support Interim Editorial Assistant: Viv Dennis (AAPM)» Editor, WG, editorial board support
12 Review improvements Current Initiatives In-house AE model Improve selectivity & stabilize Journal growth More thorough and uniform reviews Improve efficiency Improve reader experience Smaller more active Editorial Board (now 35) Advise editorial team, formulate policy, serve as AEs Implement initiatives via Working Groups» WG1: Review process efficiency, quality, selectivity» WG2: accessibility, readability, and interactivity» WG3: Data mining and evaluation of Journal quality» WG4: Outreach: Non-MP scientific/ clinical communities
13 We have increased selectivity/quality Use WG3 data to help us focus on what our audience reads and cites Discourage orphan papers that are rarely cited or read Acceptance rate Down to 45-50% from 55% We have reversed unsustainable Growth Increased focus on Best science Widely read guidance, review, and opinion
14 Review Times Median time to final decision: 88 days 1 st cycle review time: up to 42 days 25% > 60 days Median time to acceptance: 163 days from 138
15 Accomplishments Re-engineered many basic processes Improved QC Functioning process for expediting outliers Improved Correspondence and Appeals workflows New decision and invitation templates Capturing inbound s and consultation feature Major audit and evaluation of our editorial processes by Origin, Inc. All submitted papers screened by Ithenticate WG innovations WG1: review template and taxonomy WG2: Review editor position established WG3: DB established WG4: special CT and upcoming particle Tx issues
16 Dilemmas: Efficiency vs. Quality We work intensively with authors to Make poor articles with potential publishable Make acceptable articles into great articles Provide young scientists with apprenticeship in scientific writing We work hard to ensure only the high quality and innovative science gets accepted Downsides 160 days to acceptance including average of 60 days for R0 preparation Sr. scientists may view our approach as excessively critical
17 Innovations Plans for next year Complete Review Editor selection Create new section medical physics curated dataset article New EB Scientific Integrity Subcommittee (SISC)» Detailed SI/ethics standards and adjudication process Develop comprehensive marketing plan Implement Origin report recommendations BAE/GAE training Fewer chasers at smaller intervals Ask AEs to provide up front list of 4 Referees Improved & consistent Author Instructions Nurture more customer-centered culture
18 New Section: Medical Physics Dataset Articles Describe scientifically or clinically valuable openaccess datasets to help authors publish critically reviewed and documented high quality data sets to assist readers in discovering and using large-scale data sets developed by other investigators MPDAs describe the value; scope; conditions of acquisition; known limitations; and data set format No hypothesis testing or generalizable conclusions MPDA requires that the dataset be publically accessible in a recognized and stable data archive
19 New Section: Medical Physics Dataset Articles Examples large series of anonymized patient mammograms with positive or suggestive BIRADS readings and histopathologic diagnoses for CAD algorithm validation Virtual clinical trial datasets: Serial Tx-position CT datasets including validated physician organ segmentations, identified registration landmarks, and nonrigid planning-to-tx registrations Main barrier Lack of accessible dataset repositories for large scale data To date, scientific societies, e.g., AAPM, have stepped forward
20 Conclusion Medical physics research is rapidly changing More multidisciplinary More focus on imaging even in therapy New submission rapidly increasing especially from from Europe and Asia Med Phys needs to adapt, too Faster, more interactive Better understand and serve readership/authorship needs Appreciate our broad international and multidisciplinary audience Improve Med Phys impact and quality while nurturing positive aspects of its culture
In Memory of Alex Turner Medical Physics Workshop: Editorial Vision and Guidance on Writing and Reviewing Papers. Outline
The Department of Radiation Oncology In Memory of Alex Turner Medical Physics Workshop: Editorial Vision and Guidance on Writing and Reviewing Papers Russell B. Tarver, M.S. The Center for Cancer and Blood
More informationThe Roles and Task of Medical Physicists in Clinical Trial (Therapy Trials: RTOG and NRG)
1 The Roles and Task of Medical Physicists in Clinical Trial (Therapy Trials: RTOG and NRG) YING XIAO, PHD AAPM Annual Meeting, 2017 NCI National Clinical Trials Network The NCTN structure includes five
More informationTina Morrison, Ph.D. Chair, Committee on Modeling and Simulation Office of the Chief Scientist U.S. Food and Drug Administration
Tina Morrison, Ph.D. Chair, Committee on Modeling and Simulation Office of the Chief Scientist U.S. Food and Drug Administration Tina.Morrison@fda.hhs.gov Joseph Pellettiere Overview FDA s Strategic Plan
More informationMaking Models Publicly Available: Successes and Challenges
Making Models Publicly Available: Successes and Challenges Tina Morrison PhD Office of Device Evaluation Center for Devices and Radiological Health U.S. Food and Drug Administration Modeling & Simulation
More informationHow to write and publish a scientific paper (in English)
How to write and publish a scientific paper (in English) Thomas Ferkol, MD Alexis Hartmann Professor of Pediatrics Professor of Cell Biology and Physiology Washington University School of Medicine President
More informationUPICT template structure as modified by QIBA VolCT Technical Committee June 25, 2009
UPICT template structure as modified by QIBA VolCT Technical Committee June 25, 2009 The QIBA VolCT Technical Committee modified and used the UPICT template for a VolCT profile on CT Lung Nodule Volume
More informationSciTechnol Mediakit. MatheMatics. Research and Reports on. Research Journal of Clinical Pediatrics
SciTechnol Mediakit Research Journal of Clinical Pediatrics Research and Reports on MatheMatics www.scitechnol.com www.scitechnol.com Our Vision To publish, promote and disseminate the work of medical
More informationMOSAIQ. Radiation Oncology Information System. Confidence for you and your patients
MOSAIQ Radiation Oncology Information System Confidence for you and your patients MOSAIQ Radiation Oncology Information System Capture the Entire Oncology Chart in a Single Integrated Solution MOSAIQ is
More information7/22/2014. The Necessity of Innovation in Medical Physics. Disclosures. AAPM - Medical Physicists. John Bayouth, Ph.D.
The Necessity of Innovation in Medical Physics John Bayouth, Ph.D. President, AAPM Professor and Chief of Physics Department of Human Oncology University of Wisconsin Disclosures Principal employer: University
More informationAI for TB Screening Guide
AI for TB Screening Guide With AI for TB software, chest X-rays can automatically be analyzed for signs of tuberculosis. You can access through the web, standalone appliance or integrated into any PACS
More informationBiomedical engineering (BME) is the application of engineering principles and design concepts
AIHA Internet Resources Digest Supporting Access to the High Quality Online Resources August 2014 Spotlight on: Resources on Biomedical Engineering Biomedical engineering (BME) is the application of engineering
More informationRishabh Kapoor Jatinder R. Palta Daniel Yeung Anh Le University of Florida
Rishabh Kapoor Jatinder R. Palta Daniel Yeung Anh Le University of Florida Improve the connectivity of various radiation oncology hardware and software products Improve radiation oncology work flow Help
More informationOutline AAPM -- TG-127. TG and ABR. TG Scope Current General Status of MOC in eyes of TG-127 Continuing Education SAMs PQI Summary
Outline AAPM -- TG-127 Michael Yester, Ph.D. University of Alabama at Birmingham TG - 127 Scope Current General Status of MOC in eyes of TG-127 Continuing Education SAMs PQI Summary TG - 127 Scope The
More information8/3/2016. Jatinder R Palta PhD Virginia Commonwealth University and National Radiation Oncology Program Veterans Health Affairs Richmond, Virginia
Jatinder R Palta PhD Virginia Commonwealth University and National Radiation Oncology Program Veterans Health Affairs Richmond, Virginia Virtual simulation, 3D computation & optimization, IMRT, IGRT, MC
More informationSPECTArare as an innovative model of combining clinical research and care in an ERN. Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium
SPECTArare as an innovative model of combining clinical research and care in an ERN Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium Contents The changing clinical research pathway How
More informationCardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences
Cardinal Health Specialty Solutions Bringing a new drug to life Regulatory Sciences How we guided a pharma s breakthrough vision to commercial reality The right drug can mean the difference between life
More informationSpeed your time to market with FDA s expedited programs
Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In
More information8/2/2017. Key attributes of scientific excellence: rigor, innovation, and relevance. Medical Physics 3.0. Key Attributes of Scientific Excellence
Medical Physics 3.0 in Design Key attributes of scientific excellence: rigor, innovation, and relevance Maryellen Giger, Ph.D. A. N. Pritzker Professor of Radiology / Medical Physics The University of
More informationPrecision in Quantitative Imaging: Trial Development and Quality Assurance
Precision in Quantitative Imaging: Trial Development and Quality Assurance Susanna I Lee MD, PhD Thanks to: Mitchell Schnall, Mark Rosen. Dan Sullivan, Patrick Bossuyt Imaging Chain: Patient Data Raw data
More informationIs a Career in the. Pharmaceutical. Check out our online Student Center to find out more:
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right
More informationThanks to Jeff Williamson, Mike Steinberg, James Purdy
Thanks to Jeff Williamson, Mike Steinberg, James Purdy Radiation Therapy 1.6M new cancer cases this year in US Approximately 60% of cancer patients receive radiation therapy during the course of their
More informationConnect and Deliver Optima CT580 RT
GE Healthcare Connect and Deliver Optima CT580 RT Taking aim at cancer requires more than skill and compassion it takes the right connections. Radiation oncologists must connect with a CT simulator that
More informationEMRs and Disease Registries for Chronic Disease Care: Technologies and Trade-offs
EMRs and Disease Registries for Chronic Disease Care: Technologies and Trade-offs Walter Sujansky, MD PhD Health Care Information Technology 2004 November 18, 2004 Role of Information Technology in Chronic
More informationClinical and Translational Research: Expectations and Goals
Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice Dean for Clinical Investigation Clinical Research
More informationTOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
More informationBiotech Patents in Europe
Biotech Patents in Europe Introduction This circular relates to biotech patent practice in Europe. It is based on our experience of drafting and prosecuting biotech applications. The circular is written
More informationLead the way. Molecular Imaging. GE Healthcare. imagination at work
2010 General Electric Company All rights reserved. General Electric Company reserves the right to make changes in specifications and features shown herein, or discontinue the product described at any time
More informationEUROPEAN TECHNOLOGY PLATFORM NANOMEDICINE. Work plan for GA, 16th January 2008
Work plan for 2008 1 Vision In 10 years nanomedicinebased products will lead to breakthroughs in the treatment of diseases such as cardiovascular disease, cancer, CNS diseases and diabetes. 2 The ETP is
More informationRADIATION ONCOLOGY RESIDENCY PROGRAM Competency Evaluation of Resident
Resident s Name: RADIATION ONCOLOGY RESIDENCY PROGRAM Competency Evaluation of Resident Rotation: PHYS 705: Clinical Rotation 3 Inclusive dates of rotation: Aug. 25, 2015 Feb. 25, 2016 Director or Associate
More informationUS Department of Health & Human Services, Office of the National Coordinator (ONC), Nationwide Health Information Network (NHIN) Trial Implementations
US Department of Health & Human Services, Office of the National Coordinator (ONC), Nationwide Health Information Network (NHIN) Trial Implementations Update to WVHIN Board of Directors October 9, 2008
More informationImaging Systems. Gene Saragnese CEO Imaging Systems
Growth from the Core: Imaging Systems Gene Saragnese CEO Imaging Systems Imaging g Markets 2009 Imaging Markets by Region Total EUR 14.2B 1700 900 350 1550 2300 Other emerging LATAM India Greater China
More information03/08/2017. Advances and Challenges in Contour QA for Adaptive RT. Objective. Disclosures
Advances and Challenges in Contour QA for Adaptive RT Kristy K Brock, PhD, DABR, FAAPM Professor, Department of Imaging Physics Director, Image Guided Cancer Therapy Program University of Texas MD Anderson
More informationFrom Isolation to Insights
From Isolation to Insights Now more than ever healthcare organizations are called upon to deliver increased value at reduced cost. Fostering this level of optimization and continuous improvement requires
More informationEXECUTIVE SUMMARY. Overview of Autoimmune Disease Research
EXECUTIVE SUMMARY REPORT #04-013 June 2004 Price: $2,400 USD Page Count: 162 Overview of Autoimmune Disease Research Overview Each year, hundreds of millions of dollars are devoted to ing the mysteries
More informationORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
More informationInterview. Maximizing the Value of Biospecimens to Deliver New Therapies. with Clive Green, PhD, Director and Head of Sample Management at AstraZeneca
Interview Maximizing the Value of Biospecimens to Deliver New Therapies with Clive Green, PhD, Director and Head of Sample Management at AstraZeneca Introduction and Background CLIVE GREEN This ebook originated
More informationThe Roadmap Ahead for Big Data in? Radiation Oncology. Conflict of Interest Statement. Oncology Radiation Oncology Medical Physics
The Roadmap Ahead for Big Data in Radiation Oncology Sasa Mutic, PhD Professor Vice-chair of Medical Physics and Clinical Strategy Conflict of Interest Statement TreatSafely founder and partner Radialogica
More informationSummary of MRC Unit and Institute Quinquennial Reviews
Summary of MRC Unit and Institute Quinquennial Reviews The MRC carries out scientific reviews in order to be assured of: the overall quality, impact, and productivity (past and future potential) of the
More informationRisk-Based Monitoring Improves Site Performance and Investigator Satisfaction
Insight brief Risk-Based Monitoring Improves Site Performance and Investigator Satisfaction By reading this insight brief, you ll learn how RBM: Leads to earlier insights that improve trial quality Influences
More informationBravely Addressing Disputed Claims
Bravely Addressing Disputed Claims 2014 Winter Institute & Annual Meeting Indiana Pressler Memorial Chapter of HFMA February 28, 2014 John Woerly, MSA, RHIA, CHAM, FHAM (317)590-3067 john.woerly@accenture.com
More informationWhat do we need to realize in silico medicine in the future?
October 11, 2016 EU Parliament, Brussels What do we need to realize in silico medicine in the future? Modeling and Simulation at U.S. FDA Tina Morrison, Ph.D. Chair, Modeling and Simulation Working Group
More informationWelcome to the 10 th Annual Meeting of ISMPP! Leading Through Collaboration
Welcome to the 10 th Annual Meeting of ISMPP! Leading Through Collaboration 1 The Medical Publishing Insights and Practices (MPIP) Initiative: A unique collaboration between industry and journal editors,
More informationCANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
More informationBravely Addressing Disputed Claims John Woerly, RHIA, CHAM, FHAM Senior Principal, Accenture
Bravely Addressing Disputed Claims John Woerly, RHIA, CHAM, FHAM Senior Principal, Accenture Session Outline Session Objectives Defining Disputed Claims Operational Impacts Conceptual Model Organizational
More informationClinical Trials application process, legislation & guidelines
Clinical Trials application process, legislation & guidelines IMB Clinical Trials Seminar 19 th June 2012 Elaine Breslin MB BCh (NUI), PhD, FRCPI Clinical Assessment Manager 19/06/2012 Slide 1 IMB Mission
More informationGLOBAL Trend and opportunities in drug development
GLOBAL Trend and opportunities in drug development พญ อรณ ต งเผ า Oranee T Daniels MD October 2015 Looking back during last 15 years Drug safety became a focus for both regulators and drug developers.
More informationUniversity of California, San Francisco Helen Diller Family Comprehensive Cancer Center Policy and Procedure
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center Policy and Procedure PRMS Disease Site Committee Review Policy PRMS Procedure for Protocol Review by Site Committee
More informationOncology Billing Specialists
Oncology Billing Specialists ONCOLOGY Coding, Billing and Reimbursement EXPERTS When you entrust your medical billing services to RC Billing, you can rest easy knowing the details are handled to allow
More informationExpanded Access to Investigational Imaging Drugs
Expanded Access to Investigational Imaging Drugs Phillip B. Davis, MD FDA/CDER/ODEIV/DMIP 6/09/2016 1 Overview Expanded Access (EA) Defined Requirements for all EA authorizations Types of EA Individual
More informationWebinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation.
Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation. Carolinas Collaborative Pilot RFA Webinar May 8, 2017 Partners Overview
More informationFacilitating the Use of Imaging Biomarkers in Therapeutic Clinical Trials. Michael Graham, PhD, MD President, SNM Co-chair, Clinical Trials Network
Facilitating the Use of Imaging Biomarkers in Therapeutic Clinical Trials Michael Graham, PhD, MD President, SNM Co-chair, Clinical Trials Network Facilitating the Use of Imaging Biomarkers in Therapeutic
More informationAmerican Association of Pharmaceutical Scientists (AAPS)
American Association of Pharmaceutical Scientists (AAPS) AAPS, King Street, Alexandria, VA, USA* he American Association of Pharmaceu- Scientists (AAPS), founded in 1986, Ttical is an individual membership
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationIntegrating the MR-Linac into Radiation Therapy Practice
Integrating the MR-Linac into Radiation Therapy Practice Mikki Campbell MRT(T), MHE Winnie Li MRT(T), MSc UTDRO Evening Journal Club MR-Linac: From Prototype to Clinical January 24, 2019 Objectives To
More informationImplementing Biomedical Informatics Approaches to Facilitate Translational and Clinical Research
Implementing Biomedical Informatics Approaches to Facilitate Translational and Clinical Research Institute of Medicine May 30, 2014 David A. Fenstermacher, Ph.D. Chief Research Information Officer Professor,
More informationCOCIR CT Manufacturers Voluntary Commitment Regarding CT Dose 2014 Annual Report
Preamble COCIR CT Manufacturers Voluntary Commitment Regarding CT Dose 2014 Annual Report This 2 nd Annual Report defines the COCIR CT manufacturers voluntary commitment to HERCA as a result of the meeting
More informationWhile individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES
ELECTRONICALLY REPRINTED FROM JUNE 2017 CLINICAL TRIALS Rare Diseases: MEETING THE UNIQUE CHALLENGES OF ORPHAN DRUG DEVELOPMENT BY MICHAEL F. MURPHY, MD, Ph D While individually rare, orphan diseases are
More informationRoadmap for Managing Multiple CRO Vendors
PharmaSUG 2017 - Paper PO27 Roadmap for Managing Multiple CRO Vendors Veena Nataraj, Shire, Lexington, MA Karin LaPann, Shire, Lexington, MA ABSTRACT When working with CROs, the relationship established
More informationOn behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic
Robert J. Beall, Ph.D. President and Chief Executive Officer Cystic Fibrosis Foundation On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic fibrosis (CF) in the United States,
More informationHigh Profile Publishing in Molecular Biology. Hélène Hodak, Marina Ostankovitch,
High Profile Publishing in Molecular Biology Hélène Hodak, h.hodak@elsevier.com Marina Ostankovitch, m.ostankovitch@elsevier.com The field of Molecular Biology, inception to current trends Preparing a
More informationEvolution of the Healthcare Contact Center. Session 52, February 12, 2019 Lynne Hildreth, Director of Patient Access, Moffitt Cancer Center
Evolution of the Healthcare Contact Center Session 52, February 12, 2019 Lynne Hildreth, Director of Patient Access, Moffitt Cancer Center 1 Conflict of Interest Lynne Hildreth Has no real or apparent
More informationCGIR V21N1 January, It is an honor and a privilege for us to take on this new role and responsibility as
Incoming Editorial Praveen Kumar & Alessandro Zattoni It is an honor and a privilege for us to take on this new role and responsibility as editors-in-chief (EICs) of Corporate Governance: An International
More informationOECI WORKING GROUP HIGHLIGHTS
OECI WORKING GROUP HIGHLIGHTS Pathobiology Mission Statement To create European (molecular) pathology based platforms or environments that enable or improve knowledge transfer and translational research
More informationMedical Imaging Informatics Overview. Dr. Adam CHEE Chief Advocate (Director) 3 rd Nov 2010
Medical Imaging Informatics Overview Dr. Adam CHEE Chief Advocate (Director) 3 rd Nov 2010 1 About binaryhealthcare binaryhealthcare is a Social Enterprise that strive to improve healthcare (and saving
More informationEditor Guidelines. Ethics Approval and Informed Consent Statements
Editor Guidelines Ethics Approval and Informed Consent Statements Editor Guidelines: Ethics Approval and Informed Consent Statements The inclusion of ethics approval and informed consent statements is
More informationCAQH CORE Valuebased Payment (VBP) Webinar Series: Attribution Unlocking Value-based Purchasing s Full Potential, with the National Quality Forum
CAQH CORE Valuebased Payment (VBP) Webinar Series: Attribution Unlocking Value-based Purchasing s Full Potential, with the National Quality Forum 2019 CAQH, All Rights Reserved. January 17, 2019 2:00 3:00
More informationTHE ESSENTIAL ELEMENT of a
THE ESSENTIAL ELEMENT of a Successful Laboratory LabDAQ Laboratory Information System (LIS) is a scalable SOLUTION trusted by thousands of physicians and laboratory professionals every day. Experience
More informationWebinar: Knowledge-based approaches to decreasing clinical attrition rates
Webinar: Knowledge-based approaches to decreasing clinical attrition rates Speakers: Dr. Richard K. Harrison Gavin Coney Teresa Fishburne May 2018 2 Clarivate Analytics is the global leader in providing
More informationEstablishing an Optimal Operational Infrastructure
Establishing an Optimal Operational Infrastructure David Holmes III holmes.david3@mayo.edu Imaging in Clinical Trials Conference March 30 th, 2017 2015 MFMER slide-1 My Background Ph.D. in Biomedical Engineering/Imaging
More informationMaterials Technology Institute Strategic Plan for 2011, 2012 and 2013
Materials Technology Institute Strategic Plan for 2011, 2012 and 2013 Final Revision March 2011 TABLE OF CONTENTS About MTI... 1 History of MTI... 1 Scope... 1 Vision... 1 Mission... 1 Values... 2 Benefits
More informationAn Integrated Solution to Your Medical Billing & Collection Needs
An Integrated Solution to Your Medical Billing & Collection Needs 12708 Riata Vista Circle Suite A126 Austin, Texas 78727 Phone: (512) 637-2002 Fax: (512) 637-2007 www.ascend-health.com Second in importance
More informationTEXTRUM Proposing a Journal
Publishing for Academics, Scientists, Professionals and Organizations Proposing a Journal providing knowledge to your needs Proposing a Journal providing knowledge to your needs is dedicated to providing
More informationUniversity of California, San Francisco Helen Diller Family Comprehensive Cancer Center Policy and Procedure
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center Policy and Procedure PRMS Disease Site Committee Review Policy PRMS Procedure for Protocol Review by Site Committee
More informationIMMUNOTHERAPY 2008: IMPLEMENTING COMBINATIONS
8 th International Workshop IMMUNOTHERAPY 2008: IMPLEMENTING COMBINATIONS Organized by: International Union Against Cancer (UICC) Center of Molecular Immunology Cuba, November 10-14, 2008 (http://www.uicc.org)
More informationMOLECULAR DIAGNOSTICS TESTING: Industry Overview and SCM Challenges
MOLECULAR DIAGNOSTICS TESTING: Industry Overview and SCM Challenges Alan Wells, Vice President, Diagnostics Laboratory Operations, Life Technologies Mike Crowell, Sr. Director of Supply Chain, Verinata
More informationDEFINING BEST PRACTICE FOR ADVERSE EVENT REPORTING WITH INDUSTRY-SPONSORED CLINICAL TRIAL MANUSCRIPTS
11TH ANNUAL MEETING OF ISMPP DEFINING BEST PRACTICE FOR ADVERSE EVENT REPORTING WITH INDUSTRY-SPONSORED CLINICAL TRIAL MANUSCRIPTS April 28, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL
More informationPAREXEL ACCESS MANAGED ACCESS PROGRAMS
PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,
More informationSWOG
SWOG http://swog.org Page 1 of 5 pages Original Release Date: July 1985 Departments Affected: All Revision Date: April 2018 Introduction SERIOUS ADVERSE EVENTS The timely reporting of serious adverse events
More informationIntroduction DICOM and imaging Replacing film with PACS What is wrong with the scenario? Going beyond DICOM IHE impact: workflow problems
Extending DICOM to integrated information environments: IHE Steven C. Horii, MD, FACR, FSCAR Department of Radiology University of Pennsylvania Medical Center Disclosure Receive royalties from SPIE for
More informationSOLVING THE PATIENT RECRUITMENT DILEMMA
SOLVING THE PATIENT RECRUITMENT DILEMMA Katheryn Shea is Global Biobanking Lead at Brooks Life Sciences. She is an accomplished biobanking expert with 20+ years of industry experience, author of peer-reviewed
More informationTrans NCI Initiatives Role of imaging as an enabling technology
Oncology Co-Clinical Research Resources (Us) to Develop Best Practices for Quantitative (QI) in Mouse Models A Trans-NCI Initiative Larry Clarke, PhD, Branch Chief, CIP DCTD AAPM Meeting July th 0 Trans
More informationAdis Journals Overview
Adis Journals Overview Introduction Adis Rapid Publishing Service Life after publication AdisOnline.com The Adis publishing heritage The Adis Journals brand has evolved over 40 years to become synonymous
More informationClinical Evaluation of real-time, patient-centric QA using the Delta 4 Discover
Clinical Evaluation of real-time, patient-centric QA using the Delta 4 Discover Karl H Rasmussen, Ph.D.. khrasmussen@uthscsa.edu Nema Bassiri bassirin@livemail.uthscsa.edu Division of Medical Physics Cancer
More informationCARESTREAM RIS/PACS SuperPACS Architecture. A Changing Landscape
CARESTREAM RIS/PACS SuperPACS Architecture A Changing Landscape The field of radiology is in a constant state of acceleration and evolution. Each day, you handle an increasing number of exams and diagnostic
More informationExecutive Search. Chief Standards Officer
Executive Search Chief Standards Officer Client Overview Sterling Martin Associates has been retained by the Clinical Data Interchange Standards Consortium (CDISC) to search for Chief Standards Officer
More informationsocial, and population-based research conducted and supported by the National Institutes of Health (NIH). The
Statement by the Ad Hoc Group for Medical Research on FY 2015 Appropriations for the National Institutes of Health Submitted for the record on March 28, 2014, to the Subcommittee on Labor, Health and Human
More informationPractice Optimization Package:
Practice Optimization Package: Maximize the Success of your Practice You want to continue providing your patients optimal care. We can help you do it. In today s environment it takes more than clinical
More informationMARKEY CANCER CENTER STANDARD OPERATING PROCEDURES. SOP No.: MCC Type: Final
Page 1 of 11 MARKEY CANCER CENTER STANDARD OPERATING PROCEDURES SOP No.: MCC-002.03 Type: Final Title: Protocol Review and Monitoring Committee Functional Overview Approval Signature Date MCC Director
More informationCDISC Standards: Current and Future
CDISC 2010 CDISC Standards: Current and Future CDISC Japan Interchange Tokyo, Japan 20 July 2010 Rebecca D. Kush, PhD President and CEO, CDISC Clinical Research Standards (Content) (Protocol-driven Research;
More informationApplying Technologies Across the End-to-End PV Process to Increase Compliance and Quality
Applying Technologies Across the End-to-End PV Process to Increase Compliance and Quality 29 Oct 2015 Andrew Rut, Chief Executive Officer, MyMeds&Me Michael Braun-Boghos, Director of Safety Analytics,
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationScience Strategy
Science Strategy 2017-2019 September 2017 Food Safety Authority of Ireland Science Strategy, 2017-2019 CONTENTS EXECUTIVE SUMMARY 1 THE FSAI SCIENCE STRATEGY 2 SPECIFIC ACTIVITIES TO ACHIEVE THE STRATEGIC
More informationTHE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE
THE IMPACT OF ADR REPORTING ON SAFE USE OF MEDICINES IN SINGAPORE THE 10-YR EXPERIENCE Dr John Lim Dr John Lim Chief Executive Officer Health Sciences Authority Singapore 13 October 2006 Ms Chan Cheng
More informationInformation Technology for Genetic and Genomic Based Personalized Medicine. Submitted. April 23, 2008
Information Technology for Genetic and Genomic Based Personalized Medicine Submitted April 23, 2008 By The Harvard Medical School Partners HealthCare Center for Genetics and Genomics in Partnership with
More informationOptum Performance Analytics
Optum Performance Analytics A unified health care data and analytics platform Photo to come Dynamic health care market forces, fueled by delivery and payment reform, have posed many new and difficult questions
More informationARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION
ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1. The Brazilian Archives of Cardiology (Arq Bras Cardiol) is a monthly publication of the Brazilian Society
More informationOptum Performance Analytics
Optum Performance Analytics A unified health care data and analytics platform Photo to come Optum Performance Analytics Position your organization for success with Optum Performance Analytics Dynamic health
More informationServiceSPAN: Making Work Centers Work Better PRODUCTIVITY TOOLS SPECIAL. The Navigator for Enterprise Solutions IN MY OPINION CIO INSIGHTS
PRODUCTIVITY TOOLS SPECIAL The Navigator for Enterprise Solutions NOVEMBER 10-2015 CIOREVIEW.COM IN MY OPINION Hugo Vasquez, Deputy CIO, The AES Corporation CIO INSIGHTS James LaPlaine, CIO, AOL, Inc.
More informationOctober 6, Below we provide input from our community of health informatics experts regarding select portions of the Draft Guidance.
Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Submitted electronically via http://www.regulations.gov RE: Use of Public Human Genetic
More informationPractical Workflow and the Cost of Adaptive Therapy. Rojano Kashani, Ph.D., DABR Washington University School of Medicine March 7, 2015
Practical Workflow and the Cost of Adaptive Therapy Rojano Kashani, Ph.D., DABR Washington University School of Medicine March 7, 2015 Disclosures Travel expenses paid by ViewRay Inc. for on-site software
More information